NYSE:NGM - NGM Biopharmaceuticals Stock Price, News & Analysis

+0.36 (+2.29 %)
(As of 09/17/2019 03:44 PM ET)
Today's Range
Now: $16.09
50-Day Range
MA: $15.59
52-Week Range
Now: $16.09
Volume585 shs
Average Volume98,549 shs
Market Capitalization$1.06 billion
P/E RatioN/A
Dividend YieldN/A
NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include NGM282, an engineered variant of the FGF19 human hormone in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that selectively activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b early proof-of-concept clinical trials for use in the treatment of type 2 diabetes and NASH; and NGM386 and NGM395, which are engineered variants of the GDF15 human hormone for use in the treatment of obesity. Its products under development also comprise NGM120, an antagonistic antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase 1 clinical trials to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome; NGM217, an antibody in Phase 1 clinical trials to restore pancreatic islet function and increase insulin production in patients with diabetes; and NGM621, an antibody in preclinical studies to decrease levels of a protein implicated in the dry form of age-related macular degeneration. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp., MedImmune Limited, and JDRF International. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

Industry, Sector and Symbol

Industry N/A



Sales & Book Value

Annual SalesN/A



Market Cap$1.06 billion
Next Earnings Date11/11/2019 (Estimated)
OptionableNot Optionable

Receive NGM News and Ratings via Email

Sign-up to receive the latest news and ratings for NGM and its competitors with MarketBeat's FREE daily newsletter.

NGM Biopharmaceuticals (NYSE:NGM) Frequently Asked Questions

What is NGM Biopharmaceuticals' stock symbol?

NGM Biopharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "NGM."

How were NGM Biopharmaceuticals' earnings last quarter?

NGM Biopharmaceuticals (NYSE:NGM) released its quarterly earnings data on Monday, August, 12th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.71. The business earned $25.34 million during the quarter, compared to analysts' expectations of $19 million. View NGM Biopharmaceuticals' Earnings History.

When is NGM Biopharmaceuticals' next earnings date?

NGM Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November 11th 2019. View Earnings Estimates for NGM Biopharmaceuticals.

What price target have analysts set for NGM?

4 Wall Street analysts have issued 12 month target prices for NGM Biopharmaceuticals' stock. Their forecasts range from $22.00 to $29.00. On average, they expect NGM Biopharmaceuticals' share price to reach $25.50 in the next year. This suggests a possible upside of 58.5% from the stock's current price. View Analyst Price Targets for NGM Biopharmaceuticals.

What is the consensus analysts' recommendation for NGM Biopharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NGM Biopharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NGM Biopharmaceuticals.

What are Wall Street analysts saying about NGM Biopharmaceuticals stock?

Here are some recent quotes from research analysts about NGM Biopharmaceuticals stock:
  • 1. According to Zacks Investment Research, "NGM Biopharmaceuticals Inc. is focused on developing novel therapeutics for underlying cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's product pipeline consists of NGM282, NGM313, NGM120, NGM217, NGM621, NGM386 and NGM395 which are in clinical stage. NGM Biopharmaceuticals Inc. is based in San Francisco, California. " (8/27/2019)
  • 2. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating and $26 target price after NGM reported its 2Q19 financials and business update. We remain positively biased ahead of NGM282’s (aldafermin) Phase 2 cohort 4 interim data expected in 4Q19 (non-invasive biomarkers), but more importantly, aldafermin’s top line results in early 2020 where we believe it has the potential to demonstrate a histological fibrosis benefit in NASH patients in as little as 24 weeks of treatment. The latter remains the key catalyst for the stock, in our view. In the press release, NGM indicated it had completed enrollment for cohort 4 and management also highlighted pipeline progress for some of its earlier stage programs including for NGM621, which is being developed for geographic atrophy, and NGM120 for CACS." (8/14/2019)

Has NGM Biopharmaceuticals been receiving favorable news coverage?

News articles about NGM stock have been trending negative on Tuesday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. NGM Biopharmaceuticals earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for NGM Biopharmaceuticals.

What other stocks do shareholders of NGM Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NGM Biopharmaceuticals investors own include Amarin (AMRN), Translate Bio (TBIO), Intercept Pharmaceuticals (ICPT), Iovance Biotherapeutics (IOVA), JD.Com (JD), Micron Technology (MU), Aurora Cannabis (ACB), ADMA Biologics (ADMA), Alexion Pharmaceuticals (ALXN) and Beigene (BGNE).

Who are NGM Biopharmaceuticals' key executives?

NGM Biopharmaceuticals' management team includes the folowing people:
  • Mr. William J. Rieflin, Exec. Chairman of Directors (Age 59)
  • Dr. David J. Woodhouse, CEO, Acting CFO & Director (Age 48)
  • Dr. Aetna Wun Trombley, Pres & COO (Age 40)
  • Dr. Jin-Long Chen, Founder, Chief Scientific Officer & Director (Age 56)
  • Dr. Hui Tian, Sr. VP of Research

When did NGM Biopharmaceuticals IPO?

(NGM) raised $100 million in an IPO on Thursday, April 4th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Cowen served as the underwriters for the IPO.

When does the company's lock-up period expire?

NGM Biopharmaceuticals' lock-up period expires on Tuesday, October 1st. NGM Biopharmaceuticals had issued 6,666,667 shares in its public offering on April 4th. The total size of the offering was $106,666,672 based on an initial share price of $16.00. After the expiration of the company's lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Who are NGM Biopharmaceuticals' major shareholders?

NGM Biopharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Svennilson Peter (23.76%), RHO Capital Partners Inc. (5.71%), Royal Bank of Canada (1.83%), Rock Springs Capital Management LP (0.53%), Jasper Ridge Partners L.P. (0.53%) and BlackRock Inc. (0.49%). Company insiders that own NGM Biopharmaceuticals stock include David V Goeddel, Group L P Column, Merck & Co, Inc, Peter Svennilson and Suzanne Sawochka Hooper. View Institutional Ownership Trends for NGM Biopharmaceuticals.

Which major investors are buying NGM Biopharmaceuticals stock?

NGM stock was purchased by a variety of institutional investors in the last quarter, including Svennilson Peter, RHO Capital Partners Inc., Royal Bank of Canada, Rock Springs Capital Management LP, Jasper Ridge Partners L.P., BlackRock Inc., EcoR1 Capital LLC and Vanguard Group Inc.. Company insiders that have bought NGM Biopharmaceuticals stock in the last two years include David V Goeddel, Group L P Column, Merck & Co, Inc, Peter Svennilson and Suzanne Sawochka Hooper. View Insider Buying and Selling for NGM Biopharmaceuticals.

How do I buy shares of NGM Biopharmaceuticals?

Shares of NGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is NGM Biopharmaceuticals' stock price today?

One share of NGM stock can currently be purchased for approximately $16.09.

How big of a company is NGM Biopharmaceuticals?

NGM Biopharmaceuticals has a market capitalization of $1.06 billion. NGM Biopharmaceuticals employs 164 workers across the globe.View Additional Information About NGM Biopharmaceuticals.

What is NGM Biopharmaceuticals' official website?

The official website for NGM Biopharmaceuticals is http://www.ngmbio.com/.

How can I contact NGM Biopharmaceuticals?

The company can be reached via phone at 650-243-5555.

MarketBeat Community Rating for NGM Biopharmaceuticals (NYSE NGM)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  18 (Vote Outperform)
Underperform Votes:  11 (Vote Underperform)
Total Votes:  29
MarketBeat's community ratings are surveys of what our community members think about NGM Biopharmaceuticals and other stocks. Vote "Outperform" if you believe NGM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NGM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel